114 related articles for article (PubMed ID: 26034055)
21. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Tremblay D; Mesa R; Scott B; Buckley S; Roman-Torres K; Verstovsek S; Mascarenhas J
Blood Adv; 2020 Dec; 4(23):5929-5935. PubMed ID: 33275766
[TBL] [Abstract][Full Text] [Related]
22. [Janus kinase inhibitors as a new therapeutic principle].
Heinzl S
Med Monatsschr Pharm; 2012 Oct; 35(10):350-2. PubMed ID: 23094577
[No Abstract] [Full Text] [Related]
23. Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.
William AD; Lee AC
Chimia (Aarau); 2015; 69(3):142-5. PubMed ID: 26507218
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Verstovsek S; Mesa R; Talpaz M; Kiladjian JJ; Harrison CN; Oh ST; Vannucchi AM; Rampal R; Scott BL; Buckley SA; Craig AR; Roman-Torres K; Mascarenhas JO
Haematologica; 2022 Jul; 107(7):1599-1607. PubMed ID: 34551507
[TBL] [Abstract][Full Text] [Related]
25. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
26. JAK inhibitors: beyond spleen and symptoms?
Cervantes F; Mesa R; Harrison C
Haematologica; 2013 Feb; 98(2):160-2. PubMed ID: 23372034
[No Abstract] [Full Text] [Related]
27. Paradigm shift: combination BET and JAK inhibition in myelofibrosis.
Mascarenhas J; Gerds A; Verstovsek S
Leukemia; 2021 Dec; 35(12):3361-3363. PubMed ID: 34480105
[No Abstract] [Full Text] [Related]
28. What should be the endpoints of a symptomatic drug and its control?
Leone G
Lancet Haematol; 2017 May; 4(5):e197-e198. PubMed ID: 28460814
[No Abstract] [Full Text] [Related]
29. Pacritinib in Patients With Myelofibrosis.
Suzuki S; Tsuda K; Tanimoto T
JAMA Oncol; 2018 Dec; 4(12):1786-1787. PubMed ID: 30422169
[No Abstract] [Full Text] [Related]
30. Pacritinib in Patients with Myelofibrosis-Reply.
Mascarenhas JO
JAMA Oncol; 2018 Dec; 4(12):1787. PubMed ID: 30422175
[No Abstract] [Full Text] [Related]
31. The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics.
Pieri L; Loiacono I; Vannucchi AM
Leuk Res; 2013 Aug; 37(8):855-6. PubMed ID: 23726413
[No Abstract] [Full Text] [Related]
32. Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights.
Handa S; Farina KA; Becker M; Kelly B; Yu A; Feld J; Tremblay D; Marcellino BK; Salib C; Mascarenhas J; Shih AH
JCO Precis Oncol; 2024 Jan; 8():e2300234. PubMed ID: 38295318
[TBL] [Abstract][Full Text] [Related]
33. Deriving a Preference-Based Measure for Myelofibrosis from the EORTC QLQ-C30 and the MF-SAF.
Mukuria C; Rowen D; Brazier JE; Young TA; Nafees B
Value Health; 2015 Sep; 18(6):846-55. PubMed ID: 26409613
[TBL] [Abstract][Full Text] [Related]
34. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT; Savona MR; Scott BL; Talpaz M; Egyed M; Harrison CN; Yacoub A; Vannucchi A; Mead AJ; Kiladjian JJ; O'Sullivan J; García-Gutiérrez V; Bose P; Rampal RK; Miller CB; Palmer J; Oh ST; Buckley SA; Mould DR; Ito K; Tyavanagimatt S; Smith JA; Roman-Torres K; Devineni S; Craig AR; Mascarenhas JO
Blood Adv; 2020 Nov; 4(22):5825-5835. PubMed ID: 33232476
[TBL] [Abstract][Full Text] [Related]
35. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.
Masarova L; Mesa RA; Hernández-Boluda JC; Taylor JA
Leuk Res; 2020 Apr; 91():106338. PubMed ID: 32200188
[No Abstract] [Full Text] [Related]
36. Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis.
Robibaro B; Kropfmueller A; Prokop M; Haber P; Gisslinger H
Ann Hematol; 2010 Aug; 89(8):829-31. PubMed ID: 20024549
[No Abstract] [Full Text] [Related]
37. A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis.
Chen F; Zhang C; Wang W; Li L; Yan S; Sun J; Zhang M; Ji C; Hou M
Leuk Res; 2008 Apr; 32(4):665-7. PubMed ID: 17854891
[TBL] [Abstract][Full Text] [Related]
38. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
Derenzini E; Younes A
Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
[TBL] [Abstract][Full Text] [Related]
39. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW
Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275
[TBL] [Abstract][Full Text] [Related]
40. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.
Garber K
Nat Biotechnol; 2011 Jun; 29(6):467-8. PubMed ID: 21654650
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
